Here's What Key Metrics Tell Us About Altria (MO) Q3 Earnings

Altria (MO) reported $5.25 billion in revenue for the quarter ended September 2025, representing a year-over-year decline of 1.7%. EPS of $1.45 for the same period compares to $1.38 a year ago.The reported revenue represents a surprise of -1.32% over the Zacks Consensus Estimate of $5.32 billion. With the consensus EPS estimate being $1.44, the EPS surprise was +0.69%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Altria performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues net of excise taxes- Oral tobacco products: $665 million versus the two-analyst average estimate of $713.65 million. The reported number represents a year-over-year change of -4.3%.Revenues net of excise taxes- Smokeable Products: $4.59 billion versus the two-analyst average estimate of $4.64 billion. The reported number represents a year-over-year change of -1.3%.Operating Income (Loss)/ Reported OCI- Oral tobacco products: $459 million compared to the $486.18 million average estimate based on two analysts.Adjusted OCI- Smokeable Products: $2.96 billion versus $3 billion estimated by two analysts on average.Operating Income (Loss)/ Reported OCI- All Other/ Financial Services: $-76 million compared to the $-132.5 million average estimate based on two analysts.View all Key Company Metrics for Altria here>>>Shares of Altria have returned -6.5% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Altria Group, Inc. (MO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks